Cingulate Inc. financial data

Symbol
CING, CINGW on Nasdaq
Industry
Pharmaceutical Preparations
Location
1901 W. 47 Th Place, Kansas City, Kansas
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 28.2 % -82.3%
Debt-to-equity -304 % -421%
Return On Equity 914 %
Return On Assets -448 % -221%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.01M shares -55.7%
Common Stock, Shares, Outstanding 5.01M shares -55.7%
Entity Public Float 7.8M USD -32.2%
Common Stock, Value, Issued 502 USD -55.6%
Weighted Average Number of Shares Outstanding, Basic 4.95M shares +775%
Weighted Average Number of Shares Outstanding, Diluted 4.95M shares +775%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.2M USD +81.4%
General and Administrative Expense 6.69M USD -16.2%
Operating Income (Loss) -21.9M USD -33.7%
Nonoperating Income (Expense) -645K USD -92.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.5M USD -34.9%
Net Income (Loss) Attributable to Parent -22.5M USD -34.9%
Earnings Per Share, Basic -19.5 USD/shares +45.8%
Earnings Per Share, Diluted -19.5 USD/shares +91.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.11M USD -35.9%
Assets, Current 2.73M USD -27.4%
Property, Plant and Equipment, Net 2.46M USD -13.3%
Operating Lease, Right-of-Use Asset 304K USD -46.5%
Assets 5.49M USD -23.3%
Accounts Payable, Current 738K USD +23.2%
Accrued Liabilities, Current 1.12M USD +59.8%
Liabilities, Current 2.25M USD -66.3%
Operating Lease, Liability, Noncurrent 33.1K USD -91.8%
Liabilities 2.28M USD -67.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.25K USD
Retained Earnings (Accumulated Deficit) -95.9M USD -30.7%
Stockholders' Equity Attributable to Parent 3.22M USD +3841%
Liabilities and Equity 5.49M USD -23.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.75M USD -145%
Net Cash Provided by (Used in) Financing Activities 9.89M USD
Net Cash Provided by (Used in) Investing Activities -81.5K USD -119%
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 5.01M shares -55.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.06M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 308 USD -44.5%
Deferred Tax Assets, Valuation Allowance 13.4M USD +91.3%
Deferred Tax Assets, Gross 13.2M USD +123%
Operating Lease, Liability 489K USD -41%
Depreciation 646K USD +64.3%
Payments to Acquire Property, Plant, and Equipment 81.5K USD +119%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.98M USD -48.6%
Property, Plant and Equipment, Gross 5.27M USD +5.37%
Operating Lease, Liability, Current 372K USD +8.23%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 6.52M USD +92.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 415K USD +2.07%
Additional Paid in Capital 99.1M USD +34.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 564K USD +73%
Interest Expense 634K USD -83.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%